Copley Scientific Showcases New TPK™ 2100 Critical Flow Controller for Dry Powder Inhaler Testing at DDL2017

A highly automated system to speed up testing, improve reproducibility, and enhance data output and recording

Nottingham, UK: Copley Scientific, the world’s leading manufacturer of inhaler test equipment, presented its new 3rd generation Critical Flow Controller—the TPK™ 2100—for the testing of dry powder inhalers (DPIs) at the 2017 Drug Delivery to the Lungs conference (DDL2017) in Edinburgh. Now in its 27th year, DDL is the premier annual event for researchers in the field. The company showcased this latest TPK™ model at DDL to highlight a series of new capabilities, all intended to make dry powder inhaler testing more automated, more reproducible, and more efficient.

More than 700 delegates and 90 industry sponsors were expected for the 3-day meeting, which featured discussions on industry hot topics as diverse as the lessons formulators can learn from new e-cigarettes, as well as a regulatory update presentation from the European Medicines Agency (EMA).

The newly introduced TPK™ 2100 builds on Copley’s heritage of TPK™ models, an international standard in the field of DPI testing equipment, and is ideally suited to the needs of formulators and quality control scientists. It sets a new benchmark for the set-up, control, and documentation of all the parameters associated with the measurement of delivered dose uniformity and aerodynamic particle size distribution (APSD) by cascade impaction, in accordance with the United States and European Pharmacopoeias.

Anna Sipitanou, Business Development Manager at Copley Scientific, comments: “The new TPK 2100™ has already generated extremely positive feedback from customers who have interacted with it, both at RDD Europe back in April and since its launch. We think it was a big hit at DDL, as we gave live demonstrations to inhaler testing analysts and laboratory managers alike. It is rewarding to know that the advancements we have incorporated into the TPK™ 2100 look set to benefit both existing and new customers, making a substantial difference to productivity and efficiency in the execution of these important tests.”

Designed to replace the well-established TPK™ 2000, significant new features are built into the TPK™ 2100. A new ‘flyby- wire’ flow control valve allows operation to be automated. Inhaler pressure drop, P1, and test flow rate are accurately and rapidly set by the TPK™ 2100 during test set-up, whilst in-line flow measurement can be accommodated and in-situ impactor leak testing is fully automated for the first time. The user is warned if the important P3/P2 ratio is greater than 0.5, giving full confidence that tests are conducted under sonic flow conditions, whilst notification is also given if the set flow rate and impactor leak rate are outside acceptance limits. Test duration is automatically calculated based on the required test volume, and the new model offers an optional footswitch and temperature/humidity module. Data output to printer and computer are standard, with enhanced monitoring and five different reports covering critical intest parameters, whilst remote control via USB allows the TPK™ 2100 to be integrated into larger automated systems, where required. Finally, the new instrument allows users to emulate the previous generations of TPK™, promoting interchangeability and integration into existing standard operating procedures (SOPs).

A new TPK™ 2100-R is also being launched. This is a reversed version where the flow inlet and outlets are swapped over to allow different arrangements of testing equipment to be set up on the laboratory bench.

Experts from Copley Scientific were on hand throughout DDL2017 to discuss any aspect of inhaler testing. To find out more about the TPK™ 2100 or the company’s complete portfolio of equipment for inhaled drug testing, contact Copley Scientific at: or download ‘Quality Solutions for Inhaled Testing’ from:

Next Generation Impactor (NGI) system for Dry Powder Inhaler (DPI) testing, including the new TPK™ 2100.

About Copley Scientific:

Copley Scientific is recognised as the world’s leading manufacturer and supplier of inhaler test equipment and is a major provider of testing systems for other pharmaceutical dosage forms. The company is also active in detergent testing.

Copley Scientific’s pharmaceutical product range includes test equipment for: delivered dose uniformity and aerodynamic particle size measurement of metered-dose inhalers, dry powder inhalers, nebulizers, and nasal sprays, as well as tablets (dissolution, disintegration, friability, and hardness) capsules, powders, suppositories, semisolids, and transdermals.

Copley Scientific has offices in the UK and Switzerland and works in partnership with aerosol particle science experts MSP Corporation in North America.

Serving the pharmaceutical and detergent industries, Copley Scientific offers an extensive range of equipment for research, development, and quality control, as well as full validation and aftersales services. This broad range of products is supplied and supported worldwide through a network of specialist distributors. Learn more at

For further information:

Company contact:
Anna Sipitanou, Business Development Manager, Copley Scientific Limited
Colwick Quays Business Park, Private Road No. 2, Colwick, Nottingham
Tel: +44 (0)115 961 6229
Fax: +44 (0)115 961 7637

European Office (Austria, France, Germany, Italy, Switzerland)
Copley Scientific AG
Erlenstrasse 27, Postfach 152, CH-4106 Therwil, Switzerland
Tel: +41 (0)61 725 25 35
Fax: +41 (0)61 721 31 87